LENZ
LENZ Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.50
−0.14%Oct 28, 2026, 21:01 UTC
LENZ Therapeutics announced a restructuring that includes a 75% headcount reduction and projects 2027 operating expenses of $70 million to $75 million, a reduction of more than 50%.
Oct 28, 2026, 21:01 UTC
LENZ Therapeutics reported third-quarter 2026 revenue of $3.384 million, including $2.6 million in product sales, and a net loss of $30.969 million, or $0.99 per diluted share.
Source:Oct 28, 2026, 20:30 UTC
LENZ Therapeutics, Inc. reported that VIZZ product sales in the third quarter of 2026 increased 50% from the prior quarter.
Source:Oct 22, 2026, 12:00 UTC
LENZ Therapeutics announced that it will host a webcast on October 29, 2026, to report its third-quarter 2026 financial results.
Source:Aug 11, 2026, 20:05 UTC
LENZ Therapeutics reported its second quarter 2026 financial results, with total revenue of $5.5 million from VIZZ product sales and global license agreements.
Jul 6, 2026, 12:15 UTC
LENZ Therapeutics launched a new telehealth prescribing option for VIZZ to treat presbyopia.
Source:Jun 24, 2026, 12:30 UTC
LENZ Therapeutics and Arrotex Pharmaceuticals entered into an exclusive license and commercialization agreement for VIZZ in Australia and New Zealand.
Source:Jun 8, 2026, 15:35 UTC
LENZ Therapeutics granted Everest Medicines the rights to develop and commercialize its presbyopia drug VIZZ (LNZ100) in Greater China.
Source: